Repurposing Rasagiline Mesylate Nanoparticles for Antidepressant Activity: <i>in silico</i> and <i>in vitro</i> Investigations

Depression is a prevalent mental health disorder that significantly impacts quality of life, yet existing treatments often exhibit delayed onset and adverse side effects. Drug repurposing offers a promising strategy to overcome these limitations by identifying new therapeutic uses for established drugs. Rasagiline Mesylate (RM), a selective Monoamine Oxidase-B (MAO-B) inhibitor commonly prescribed for Parkinson�s disease, has recently shown potential antidepressant effects. This study aimed to investigate the antidepressant potential of RM by developing a novel chitosan-based nanoparticle formulation and evaluating its activity through in silico and in vitro methodologies. Molecular docking studies demonstrated strong binding interactions between RM and serotonin receptors implicated in mood regulation, suggesting a mechanistic basis for antidepressant action. RM-loaded chitosan nanoparticles were synthesised using ionic gelation and characterised for particle size, zeta potential, and drug loading efficiency. In vitro cytotoxicity assays using PC12 neuronal cells revealed high cell viability, indicating the formulation�s biocompatibility. Additionally, serotonin uptake inhibition assays suggested enhanced antidepressant potential of the nanoparticle formulation compared to the pure drug. The results highlight the potential of RM-loaded chitosan nanoparticles as a promising therapeutic candidate for depression, warranting further preclinical and clinical investigations. Major Findings: The study investigates the repurposing of Rasagiline Mesylate (RM), a drug primarily used for Parkinson�s disease, as an antidepressant. Using in silico molecular docking, the findings show RM�s potential to interact with serotonin receptors, suggesting antidepressant-like effects. Furthermore, RM-loaded chitosan nanoparticles demonstrated enhanced bioavailability and improved cell viability in vitro, supporting the drug�s neuroprotective properties and potential as a treatment for de

View article page

Download PDF